SEC Form 8-K filed by Biolase Inc.

$BIOL
Medical/Dental Instruments
Health Care
Get the next $BIOL alert in real time by email
8-K
false000081124000008112402024-10-022024-10-02

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 2, 2024

BIOLASE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36385

87-0442441

(State or other jurisdiction of incorporation)

(Commission File No.)

(IRS Employer Identification No.)

27042 Towne Centre Drive, Suite 270

Lake Forest, California 92610

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (949) 361-1200

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

 N/A

N/A

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 2, 2024, BIOLASE, Inc. (the “Company”) received notice from OTC Markets Group, Inc. (the “OTC”) that the Company no longer meets the Standards for Continued Eligibility for OTCQB as per the OTCQB Standards, Section 2.3(5). The Company’s shares of common stock commenced trading on the Pink Market platform operated by the OTC at the market open on October 3, 2024 under the “BIOLQ” ticker symbol. Existing stockholders will find the securities quoted on the OTC Pink Market and freely tradable without any further action needed.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

BIOLASE, INC.

Date: October 8, 2024

By:

/s/ John R. Beaver

Name:

John R. Beaver

Title:

Director, President and Chief Executive Officer

(Principal Executive Officer)


Get the next $BIOL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BIOL

DatePrice TargetRatingAnalyst
More analyst ratings

$BIOL
Press Releases

Fastest customizable press release news feed in the world

See more
  • BIOLASE Voluntarily Initiates Chapter 11 Proceedings

    LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.The Company also announced today that it is pursuing a sale process under Section 363 of the Bankruptcy Code in conjunction with the filing. To this end, BIOL

    $BIOL
    Medical/Dental Instruments
    Health Care
  • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

    LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

    $BIOL
    Medical/Dental Instruments
    Health Care
  • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

    DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

$BIOL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BIOL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BIOL
SEC Filings

See more

$BIOL
Leadership Updates

Live Leadership Updates

See more
  • Strateos Appoints Alexander K. Arrow as Chief Financial Officer and Expands Team

    Juliet M. Moritz appointed Vice President, Project Management Office Strateos, Inc., a pioneer in the development of remote access laboratories and lab automation software for life science research, today announced the appointment of Alexander K. Arrow, MD, CFA, as Chief Financial Officer. Dr. Arrow will join the Executive Leadership team and play a key role in leading the company's business and finance strategy focused on growth and new investments. The company has also named Juliet M. Moritz, MPH, Vice President, Project Management Office, reflecting the significant demand by large pharmaceutical companies and contract research organizations for deployment of Strateos Lodestar™ Software.

    $BIOL
    Medical/Dental Instruments
    Health Care
  • BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER

    Dr. Morrow brings extensive clinical, dental and DSO experience to help expand laser adoption globally LAKE FOREST, Calif., Oct. 13, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced the appointment of Russell Morrow, D.D.S. as Chief Dental Officer ("CDO"), effective November 1, 2022. Dr. Samuel Low, who has served as Chief Dental Officer since 2016, will be taking on a new role as Vice President, Clinical Strategic Alliances, where he will focus on building partnerships and growth with Dental Service Organizations (DSOs), universities and government institutions.

    $BIOL
    Medical/Dental Instruments
    Health Care
  • BIOLASE Expands Core Capabilities As It Appoints Three New Board Members With Significant Dental Experience

    FOOTHILL RANCH, Calif., Aug. 16, 2021 /PRNewswire/ -- Demonstrating a deep commitment to expanding the core capabilities and diversity of its Board of Directors, BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced it has appointed three new board members to its Board of Directors (the "Board"), effective immediately. Drs. Kathleen T. O'Loughlin, Carol Gomez Summerhays, and Martha Somerman join a Board that has been instrumental in establishing and implementing the Company's business plan, which has demonstrated significant growth over the past several quarters.

    $BIOL
    Medical/Dental Instruments
    Health Care

$BIOL
Financials

Live finance-specific insights

See more
  • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

    LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

    $BIOL
    Medical/Dental Instruments
    Health Care
  • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

    DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability

    Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and SuccessLAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024.First Quarter Financial HighlightsGenerated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialistsThird strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptionsGross margin was re

    $BIOL
    Medical/Dental Instruments
    Health Care

$BIOL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more